Erudio Healtherudio.com
Clinical trial · no report yet · Phase 1/Phase 2
LINKER-AL2
A Trial to Learn if Linvoseltamab is Safe and Works in Adults With Relapsed or Refractory Systemic Light Chain Amyloidosis (AL Amyloidosis)
- NCT06292780 ↗
- Recruiting
- Regeneron Pharmaceuticals
- Standard
We haven't built an HCP commentary report on LINKER-AL2 (linvoseltamab in relapsed or refractory systemic light chain amyloidosis) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on LINKER-AL2 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 10 | |
| YouTube | 3 | |
| Podcasts | 1 |
The trial
ClinicalTrials.gov- Official title
- A Phase 1/2 Study of Linvoseltamab in Patients With Relapsed or Refractory Systemic Light Chain Amyloidosis
- Phase
- Phase 1/Phase 2
- Status
- Recruiting
- Conditions
- Relapsed/Refractory Systemic Light Chain Amyloidosis
- Interventions
- Linvoseltamab
- Arms
- Phase 1: Cohort 1: Low Dose · Experimental
- Phase 1: Cohort 2: High Dose · Experimental
- Phase 2: Low Dose · Experimental
- Phase 2: High Dose · Experimental
- Enrollment
- 220 (estimated)
- Primary outcomes
- Incidence of dose-limiting toxicity (DLTs)
- Achievement of hematologic complete response (CR) as determined by the Independent Review Committee (IRC)
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Aug 7, 2024
- Primary completion
- Aug 20, 2028 (estimated)
- Results posted
- No
- Registry record
- NCT06292780 · updated Aug 18, 2026